TNS has filed the provisional use patent entitled: "Anti-Inflammatory Approach to Prevention and Suppression of Post-Traumatic Stress Disorder (PTSD), Traumatic Brain Injury (TBI), Depression and Associated Disease States."
The formulation is reportedly composed of phytonutrients and enriched mushrooms having enhanced vitamin D and Ergothioneine.
"Research to date on the naturally-occurring antioxidants in Ergo-D Traum suggests that this novel formulation of organic mushrooms and phytonutrients has the potential to suppress inflammation of the brain associated with PTSD, TBI and depression," said Marvin Hausman M.D., CEO of TNS.
"Our company intends to organize a clinical study, during the 2nd quarter of 2011, to validate the benefits of Ergo-D Traum in patients with PTSD and TBI. TNS' proprietary ERGO and vitamin D2 technology will form the basis for the nutritional value of this new product," he added.
Post-traumatic stress disorder, often abbreviated as PTSD, is a complex disorder in which the affected person's memory, emotional responses, intellectual processes, and nervous system have all been disrupted by one or more traumatic experiences. A common causative link to many, if not all, of the physiologic disorders associated with PTSD is inflammation, said TNS.
According to the company, over 40,000 military service members have been injured in the current conflicts in Iraq and Afghanistan and that over 300,000 suffer from PTSD or depression. A report by the Veterans Administration (VA) issued in the spring of 2010 estimates that 18 veterans die by suicide every day.